Korsana Biosciences (KRSA) vs Syndax Pharmaceuticals (SNDX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Korsana Biosciences (KRSA) has outperformed Syndax Pharmaceuticals (SNDX) over the past year, gaining 90.0% versus a gain of 2.4%. Over five years, SNDX leads with a -9.1% price change compared with -91.1% for KRSA. Korsana Biosciences is the larger company by market cap ($1.53 billion vs $1.51 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KRSA | SNDX |
|---|---|---|
| Share price | $33.51 | $16.90 |
| Market cap | $1.53B | $1.51B |
| 1-day change | +6.37% | -0.76% |
| YTD return | +276.94% | -19.56% |
| 1-year return | +89.97% | +2.42% |
| 5-year return | -91.10% | -9.09% |
| EPS (TTM) | $-7.07 | $-2.52 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $59.36 | $25.59 |
| 52-week low | $7.19 | $12.99 |
| Distance from 52-week high | -43.55% | -33.96% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +31.30% | +122.19% |
| Average volume | 29.26K | 1.54M |
| Shares outstanding | 45.54M | 89.30M |
| Employees | 19 | 298 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KRSA has outperformed SNDX by 87.5 percentage points over the past year.
About Korsana Biosciences
KRSA stock →Korsana Biosciences, Inc. develops therapeutic antibodies for the treatment of neurodegenerative diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 19 employees
About Syndax Pharmaceuticals
SNDX stock →Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 298 employees
KRSA vs SNDX FAQ
Which is bigger, Korsana Biosciences or Syndax Pharmaceuticals?
Korsana Biosciences (KRSA) is larger, with a market capitalization of $1.53B compared with $1.51B for Syndax Pharmaceuticals (SNDX).
Which stock has performed better over the past year, KRSA or SNDX?
KRSA returned +89.97% over the past 12 months, compared with +2.42% for SNDX (price return, excluding dividends). Past performance does not predict future results.
Are Korsana Biosciences and Syndax Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.